• 1
    Matsushita M. What is Alzheimer's disease? Brain Sci 2000; 22: 1318 (in Japanese).
  • 2
    Jorm AF, Jolley D. The incidence of dementia: A meta-analysis. Neurology 1998; 51: 728733.
  • 3
    Watanuki Y, Urakami K, Adachi Y et al. Epidemiology in Alzheimer type dementia. Brain Sci 2000; 22: 2126 (in Japanese).
  • 4
    Nakamura S. A guideline for the treatment of dementia in Japan. Intern Med 2004; 43: 1829.
  • 5
    Tohgi H, Homma A, Imai Y et al. Long-term safety and efficacy of acetylcholinesterase inhibitor E2020 in patients with Alzheimer-type dementia: 52-week open label study. Rinsho Hyoka 2000; 28: 97126 (in Japanese).
  • 6
    Kono K. Clinical evaluation of donepezil, the 1st report: Over 3 months of donepezil treatment improved 51% of 221 patients with either Alzheimer's disease or Pick's disease. Rinsho Seisin Yakuri 2000; 3: 10531060 (in Japanese).
  • 7
    O'Brien J, Ames D, Burns A. Dementia, 2nd edn. London: Arnold, 2000.
  • 8
    Imai Y, Hasegawa K. The revised Hasegawa's dementia scale (HDS-R): Evaluation of its usefulness as a screening test for dementia. J Hong Kong Coll Psychiatry 1994; 4: 2024.
  • 9
    Rogers SL, Doody RS, Pratt RD et al. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: Final analysis of a US multicentre open-label study. Eur Neuropsychopharmacol 2000; 10: 195203.
  • 10
    Rogers SL, Friedhoff LT. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: An interim analysis of the results of a US multicentre open label extension study. Eur Neuropsychopharmacol 1997; 31: 6775.
  • 11
    AD 2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): Randomized double-blind trial. Lancet 2004; 363: 21052115.
  • 12
    Kivipelto M, Helkala E-L, Laakso MP et al. Midlife vascular risk factors and Alzheimer's disease in laterlife: Longitudinal, population based study. BMJ 2001; 322: 14471451.
  • 13
    Otto A, Stolk RP, Van Harskamp F et al. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 1999; 53: 19371942.
  • 14
    Borroni B, Colciaghi F, Pastorino L et al. ApoE gynotype influences the biological effect of donepezil on APP metabolism in Alzheimer disease: Evidence from a peripheral model. Eur Neuropsychopharmacol 2002; 12: 195200.
  • 15
    Bizzarro A, Marra C, Acciarri A et al. Apolipoprotain E e4 allele differentiates the clinical response to donepezil in Alzheimer's disease. Dement Geriatr Cogn Disord 2005; 20: 254261.
  • 16
    Rigaud AS, Traykov L, Latour F et al. Presence or absence of at least one e4 allele and gender are not predictive for the response to donepezil treatment in Alzheimer's disease. Pharmacogenetics 2002; 12: 415420.
  • 17
    Winblad B, Engedal K, Soininen H et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001; 57: 489495.
  • 18
    Rogers SL, Farlow MR, Doody RS et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998; 50: 136145.
  • 19
    Burns A, Gauthier S, Perdomo C. Efficacy and safety of donepezil over 3 years: An open-label, multicentre study in patients with Alzheimer's disease. Int J Geriatr Psychiatry 2007; 22: 806812.